H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Sage Therapeutics to $50 from $55 and keeps a Neutral rating on the shares post the Q3 results. Published first on TheFly See Insiders’ Hot Stocks on TipRanks >>